FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2525791374> ?p ?o ?g. }

• W2525791374 abstract "Abstract Abstract 2804 Background: The “monosomal karyotype” cytogenetic subgroup (MK+), as defined by Breems et al. (1) encompasses mostly complex karyotypes (CK, >3 abnormalities) and is associated with very poor outcome in AML (1, 2) and MDS (3). Discussions are ongoing regarding treatment response prediction, and a prognosis-modifying effect within the CK+ AML subgroup (1, 4). In a study of 227 AML pts >60 years, 38 of whom were MK+, we found that particularly pts with at least 2 monosomal autosomes (MK2+, by definition also CK+) appeared to benefit from DAC (5). We now applied this question to higher-risk MDS pts randomized to either DAC or Best supportive care (BSC) in the 06011 trial (6) which explicitly enrolled pts with IPSS poor-risk cytogenetics. Methods: Of 233 randomized pts, 206 had cytogenetics informative for MK status: 63 had normal cytogenetics (CN), 143 had cytogenetic abnormalities (CA) without MK (MK-, n=73) or with MK (MK+, n=70). This last group was further subdivided into pts with 1, 2 or at least 3 monosomal autosomes (MK1, MK2, MK3+, n=17, 22, 31, resp.). Endpoints were overall survival (OS), progression-free survival (PFS) and response rate (RR, complete and partial remissions, hematologic improvement). Analysis was based on the intent-to-treat principle. Results: As recently published (6), in the overall 233 pts, PFS was significantly improved in the DAC arm as compared to BSC (median 0.55 vs 0.25 years, hazard ratio [HR] 0.68, p=0.004), but not OS (HR 0.88), probably due to post-progression treatments, suboptimal DAC schedule and treatment duration as possible confounders. In the 206 pts with informative cytogenetics, significant improvement in outcome with DAC vs. BSC was also seen for PFS (p=0.022, HR 0.72, Table 1) but not OS (HR 0.93). The improvement of PFS with DAC vs BSC was quite pronounced in the 63 pts with CN (HR 0.55, p=0.03), but less impressive and not significant in the 143 pts with CA (HR 0.76, p=0.11). When subdividing the latter by MK categories, pts with either 2 (MK2) or more than 2 (MK3+) monosomal autosomes also had significantly prolonged PFS with DAC, reflected in RR of 67% in MK2 and 33% in MK3+ DAC-treated pts (Table 1). This effect was not obvious in the MK1 subgroup, where the PFS outcome was favorable in both treatment groups, and in the MK− subgroups, either without (“MK−/CK−”) or with complex karyotype (“MK−/CK+”), the latter having a very poor outcome in both treatment groups. With caution (considering the limited size of some subgroups), these results support our observation that AML pts with a complex karyotype harboring 2+ monosomies can gain benefit from this hypomethylating agent. Conclusions: This first randomized trial addressing the predictive value of the MK genotype in the presence of 2+ monosomies embedded in a complex karyotype demonstrates a very rapid deterioration of MDS pts receiving BSC (within <6 weeks from randomization with 3+ monosomies). DAC treatment mitigated the negative effect of these karyotypes. We speculate that this effect is linked to the distinct mechanism of action of the hypomethylating agent DAC (7), and that with a different DAC schedule and longer treatment duration, these effects might be observed also on OS. Disclosures: No relevant conflicts of interest to declare." @default.
• W2525791374 created "2016-10-07" @default.
• W2525791374 creator A5005056245 @default.
• W2525791374 creator A5005172825 @default.
• W2525791374 creator A5011540358 @default.
• W2525791374 creator A5012072301 @default.
• W2525791374 creator A5013231760 @default.
• W2525791374 creator A5020621642 @default.
• W2525791374 creator A5025857936 @default.
• W2525791374 creator A5026255080 @default.
• W2525791374 creator A5027406180 @default.
• W2525791374 creator A5031364930 @default.
• W2525791374 creator A5034871851 @default.
• W2525791374 creator A5037134717 @default.
• W2525791374 creator A5043494139 @default.
• W2525791374 creator A5047951694 @default.
• W2525791374 creator A5050935012 @default.
• W2525791374 creator A5061008141 @default.
• W2525791374 creator A5072099748 @default.
• W2525791374 creator A5079124367 @default.
• W2525791374 creator A5079852624 @default.
• W2525791374 creator A5090793417 @default.
• W2525791374 date "2012-11-16" @default.
• W2525791374 modified "2023-10-01" @default.
• W2525791374 title "Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011." @default.
• W2525791374 doi "https://doi.org/10.1182/blood.v120.21.2804.2804" @default.
• W2525791374 hasPublicationYear "2012" @default.
• W2525791374 type Work @default.
• W2525791374 sameAs 2525791374 @default.
• W2525791374 citedByCount "0" @default.
• W2525791374 crossrefType "journal-article" @default.
• W2525791374 hasAuthorship W2525791374A5005056245 @default.
• W2525791374 hasAuthorship W2525791374A5005172825 @default.
• W2525791374 hasAuthorship W2525791374A5011540358 @default.
• W2525791374 hasAuthorship W2525791374A5012072301 @default.
• W2525791374 hasAuthorship W2525791374A5013231760 @default.
• W2525791374 hasAuthorship W2525791374A5020621642 @default.
• W2525791374 hasAuthorship W2525791374A5025857936 @default.
• W2525791374 hasAuthorship W2525791374A5026255080 @default.
• W2525791374 hasAuthorship W2525791374A5027406180 @default.
• W2525791374 hasAuthorship W2525791374A5031364930 @default.
• W2525791374 hasAuthorship W2525791374A5034871851 @default.
• W2525791374 hasAuthorship W2525791374A5037134717 @default.
• W2525791374 hasAuthorship W2525791374A5043494139 @default.
• W2525791374 hasAuthorship W2525791374A5047951694 @default.
• W2525791374 hasAuthorship W2525791374A5050935012 @default.
• W2525791374 hasAuthorship W2525791374A5061008141 @default.
• W2525791374 hasAuthorship W2525791374A5072099748 @default.
• W2525791374 hasAuthorship W2525791374A5079124367 @default.
• W2525791374 hasAuthorship W2525791374A5079852624 @default.
• W2525791374 hasAuthorship W2525791374A5090793417 @default.
• W2525791374 hasConcept C104317684 @default.
• W2525791374 hasConcept C126322002 @default.
• W2525791374 hasConcept C143998085 @default.
• W2525791374 hasConcept C150194340 @default.
• W2525791374 hasConcept C168563851 @default.
• W2525791374 hasConcept C190727270 @default.
• W2525791374 hasConcept C207103383 @default.
• W2525791374 hasConcept C2780235182 @default.
• W2525791374 hasConcept C44249647 @default.
• W2525791374 hasConcept C54355233 @default.
• W2525791374 hasConcept C71924100 @default.
• W2525791374 hasConcept C86803240 @default.
• W2525791374 hasConcept C90924648 @default.
• W2525791374 hasConceptScore W2525791374C104317684 @default.
• W2525791374 hasConceptScore W2525791374C126322002 @default.
• W2525791374 hasConceptScore W2525791374C143998085 @default.
• W2525791374 hasConceptScore W2525791374C150194340 @default.
• W2525791374 hasConceptScore W2525791374C168563851 @default.
• W2525791374 hasConceptScore W2525791374C190727270 @default.
• W2525791374 hasConceptScore W2525791374C207103383 @default.
• W2525791374 hasConceptScore W2525791374C2780235182 @default.
• W2525791374 hasConceptScore W2525791374C44249647 @default.
• W2525791374 hasConceptScore W2525791374C54355233 @default.
• W2525791374 hasConceptScore W2525791374C71924100 @default.
• W2525791374 hasConceptScore W2525791374C86803240 @default.
• W2525791374 hasConceptScore W2525791374C90924648 @default.
• W2525791374 hasLocation W25257913741 @default.
• W2525791374 hasOpenAccess W2525791374 @default.
• W2525791374 hasPrimaryLocation W25257913741 @default.
• W2525791374 hasRelatedWork W1902925323 @default.
• W2525791374 hasRelatedWork W1979650445 @default.
• W2525791374 hasRelatedWork W2019612203 @default.
• W2525791374 hasRelatedWork W2278956317 @default.
• W2525791374 hasRelatedWork W2294107774 @default.
• W2525791374 hasRelatedWork W2352670903 @default.
• W2525791374 hasRelatedWork W2420520824 @default.
• W2525791374 hasRelatedWork W2465881045 @default.
• W2525791374 hasRelatedWork W2493897520 @default.
• W2525791374 hasRelatedWork W2527057072 @default.
• W2525791374 hasRelatedWork W2548738881 @default.
• W2525791374 hasRelatedWork W2554676127 @default.
• W2525791374 hasRelatedWork W2558194728 @default.
• W2525791374 hasRelatedWork W2558701603 @default.
• W2525791374 hasRelatedWork W2567944440 @default.
• W2525791374 hasRelatedWork W2582438422 @default.
• W2525791374 hasRelatedWork W2588213982 @default.
• W2525791374 hasRelatedWork W2589439052 @default.
• W2525791374 hasRelatedWork W2609323007 @default.
• W2525791374 hasRelatedWork W2980049937 @default.

• next